RxDoctor Payments Data

Tabitha Schilly

Family · Henderson, NCNPI 1720657729

Payments from drug & device makers

$1,613in general payments, 2019–2025

Across 86 payments — averaging $18.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$475
  • Bayer$277
  • Travere Therapeutics, Inc.$192
  • Otsuka America Pharmaceutical, Inc.$177
  • Amgen$117
  • Lilly USA, LLC$94
  • plus $283 from 8 others

What the payments were for

  • Food & beverage$1,613100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,613 in reported general payments places this provider in the 75th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$45,120
Medicare patients
253
Services billed
588

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol203$162,035
JardianceEmpagliflozin57$37,828
KerendiaFinerenone15$14,939
LokelmaSodium Zirconium Cyclosilicate16$9,070
DapagliflozinDapagliflozin Propanediol18$8,545
EntrestoSacubitril/Valsartan12$7,764
Potassium Chloride245$2,942
Verapamil SrVerapamil Hcl14$2,500
Calcium Acetate24$2,048
Amlodipine Besylate254$1,920
Isosorbide Dinitrate25$1,904
Hydralazine Hcl121$1,815
Torsemide80$1,716
Allopurinol180$1,552
Furosemide288$1,295

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$475$171,105219 claims
Boehringer IngelheimJardiance$80$37,82857 claims
BayerKerendia$277$14,93915 claims
NovartisEntresto$34$7,76412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,522 family providers in North Carolina.

Other family in Henderson

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →